Carbetocin, Postpartum Hemorrhage
Conditions
Keywords
Postpartum hemorrhage, PPH, Carbetocin, Placental retention
Brief summary
Postpartum haemorrhage (PPH) is one of the major contributors to maternal mortality and morbidity worldwide. Active management of the third stage of labour has been proven to be effective in the prevention of PPH. Syntometrine is more effective than oxytocin but is associated with more side effects. Carbetocin, a long-acting oxytocin agonist, appears to be a promising agent for the prevention of PPH. The use of carbetocin, being an important agent in the prevention of PPH, also increases its prevalence. It is planned to investigate the advantages and disadvantages of the timing of its use.
Interventions
BEHAVIORALCarbetocin
Use of carbetocin
Sponsors
Mehmet Mete Kırlangıç
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Singleton pregnancy * Vaginal delivery at or beyond 38 weeks of gestation * Primipar
Exclusion criteria
* Multiparity * Contraindications to carbetocin use (e.g., pre-existing hypertension, pre-eclampsia,asthma, cardiac, renal, or liver disease) * High-risk factors for primary postpartum hemorrhage, including grand multiparity,presence of uterine fibroids, or a need for prophylactic oxytocin infusion * Anemia or * body mass index (BMI) over 35 * Baby weight over 4000 grams * Comorbidities or chronic diseases * History of curettage * Use of propess or oxytocin during labor
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Carbetosin effect | 24 hours after delivery | incidence of postpartum hemorrhage \>500 ml (percent (%)), additional uterotonics using (yes/no), placenta retention (yes/no), adverse effects (hypotension (yes/no), tachycardia (yes/no), headache(yes/no) oliguria (yes/no)), |
Countries
Turkey (Türkiye)
Outcome results
None listed